Want to see HK:3347 full AI Analyst Report?
3347 Stock Chart & Stats
HK$54.00
HK$0.35(1.23%)
At close: 4:00 PM EST
HK$54.00
HK$0.35(1.23%)
Day’s Range― - ―
52-Week RangeHK$28.12 - HK$60.60
Previous CloseN/A
Volume678.40K
Average Volume (3M)2.64M
Market Cap
HK$40.43B
Enterprise ValueHK$29.22B
Total Cash (Recent Filing)HK$2.20B
Total Debt (Recent Filing)HK$1.53B
Price to Earnings (P/E)54.7
Beta1.74
Next Earnings
Aug 29, 2026EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)0.90
Shares Outstanding123,124,800
10 Day Avg. Volume1,735,173
30 Day Avg. Volume2,642,557
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$53.03Price Target Upside-1.81% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1.24
Revenue Forecast (FY)HK$8.81B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageLow leverage (debt ≈7% of equity TTM) provides durable financial flexibility for a CRO facing multi-year trials and milestone timing. This reduces refinancing risk, supports countercyclical investment or M&A, and preserves liquidity through longer drug development cycles.
Positive And Growing Free Cash FlowConsistent, growing FCF (≈83% of net income TTM) demonstrates sustainable cash generation from operations. For a service-led CRO, reliable FCF funds working capital, organic investment in capabilities, and optional shareholder returns without over-reliance on external financing.
CRO Model With International, Diversified ServicesTigermed's CRO model targets secular outsourcing trends in pharma R&D, offering clinical, regulatory and data services across therapeutic areas and geographies. Diversified service lines and international reach support steady demand and reduce single-market dependency over the medium term.
Bears Say
Margin And Return Compression Vs Peak YearsMeaningful margin and return compression from 2021–2022 peaks, including a 2024 revenue dip, suggests lasting pressure from pricing, competitive intensity, or mix shifts. Persistent lower margins reduce reinvestment capacity and lower the buffer against trial timing volatility.
Weaker Operating Cash Conversion RecentlyA decline in operating cash conversion (OCF covering a smaller portion of earnings) raises concerns about earnings quality and working capital management. Over months this can constrain funding for study setups, slow vendor payments, and increase reliance on cash reserves or external financing.
Modest Returns On Equity / Capital EfficiencyROE around 4% TTM signals limited efficiency in converting assets and equity into profits. Over time, low capital returns can depress shareholder value, limit self-funded growth, and indicate either margin pressure or an oversized asset base relative to revenue.
Hangzhou Tigermed Consulting Co., Ltd. Class H News
3347 FAQ
What was Hangzhou Tigermed Consulting Co., Ltd. Class H’s price range in the past 12 months?
Hangzhou Tigermed Consulting Co., Ltd. Class H lowest stock price was HK$28.12 and its highest was HK$60.60 in the past 12 months.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap is HK$40.43B.
When is Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date is Aug 29, 2026 which is in 44 days.
How were Hangzhou Tigermed Consulting Co., Ltd. Class H’s earnings last quarter?
Hangzhou Tigermed Consulting Co., Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.069 earnings per share for the quarter, missing the consensus estimate of HK$0.274 by -HK$0.205.
Is Hangzhou Tigermed Consulting Co., Ltd. Class H overvalued?
According to Wall Street analysts Hangzhou Tigermed Consulting Co., Ltd. Class H’s price is currently Overvalued.
Does Hangzhou Tigermed Consulting Co., Ltd. Class H pay dividends?
Hangzhou Tigermed Consulting Co., Ltd. Class H pays a Annually dividend of HK$0.145 which represents an annual dividend yield of 0.8%. See more information on Hangzhou Tigermed Consulting Co., Ltd. Class H dividends here
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate is 0.28.
How many shares outstanding does Hangzhou Tigermed Consulting Co., Ltd. Class H have?
Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding.
What happened to Hangzhou Tigermed Consulting Co., Ltd. Class H’s price movement after its last earnings report?
Hangzhou Tigermed Consulting Co., Ltd. Class H reported an EPS of HK$0.069 in its last earnings report, missing expectations of HK$0.274. Following the earnings report the stock price went up 3.772%.
Which hedge fund is a major shareholder of Hangzhou Tigermed Consulting Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3347
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hangzhou Tigermed Consulting Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
3.69%
Trailing 12-Months
Asset Growth
-1.34%
Trailing 12-Months
Company Description
Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
3347 Stock 12 Month Forecast
Average Price Target
HK$53.03
▼(-1.81% Downside)
Technical Analysis
WuXi AppTec Co., Ltd. Class H
―
JOINN Laboratories (China) Co., Ltd. Class H
―
Mega Genomics Limited
―
ADICON Holdings Limited
―
WuXi XDC Cayman, Inc.
―